United Drug reports positive data for third quarter

United Drug has reported positive financial data for the third quarter of the 2012 business year.

During the three-month period ending on June 30th 2012, the firm has seen profit levels across its major divisions experience year-on-year improvements, while it has also agreed deals to acquire Pharmexx and Watermeadow Medical.

Additionally, it has been able to continue the expansion of its international operations, with more than 70 percent of its corporate profits now coming from outside its domestic market of Ireland.

As a result, United Drug now expects adjusted diluted earnings per share for the year to September 30th 2012 to be between eight and ten percent ahead of 2011.

The firm said: "With strong cash flows and modest debt levels, the group remains well-positioned to support its future growth objectives both organically and through additional acquisitions."

Operating in five major international markets, United Drug currently employs more than 4,500 people across the world.